ZyStor Therapeutics, Inc. is a biotechnology company developing innovative therapeutics that will significantly improve the lives of patients who suffer from genetic disorders known as lysosomal storage diseases (LSDs).  There are more than 40 known LSDs, each caused by a deficiency in a different lysosomal enzyme.  ZyStor has acquired from St. Louis – based Symbiontics, Inc. a novel, proprietary technology, known as Glycosylation Independent Lysosomal Targeting (GILT), which improves the delivery of therapeutics that replace the missing lysosomal enzyme in LSD patients.  ZyStor has demonstrated in cell culture and in a well-characterized animal model that the GILT technology provides several distinct advantages over other LSD therapeutics

Based in Milwaukee, Wisconsin at the Innovation Center in the Milwaukee County Research Park, ZyStor recently completed the first tranche of an $8.5 million financing.   Mason Wells and Venture Investors led the syndicate of seven venture funds that participated in this financing. This syndicate also included Prolog Ventures, the State of Wisconsin Investment Board, Hexagon Investments, Apjohn Ventures and Stonehenge Capital.